ANDA 202545, held by SigmaPharm Laboratories. Griseofulvin, Ultramicrosize.
As of Nov 21, 2026, ANDA 202545 (Griseofulvin,Ultramicrosize), held by SigmaPharm Laboratories, was first approved by FDA on Oct 22, 2012, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ultramicrosize Griseofulvin Tablets, USP are indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis, Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum …
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2012 | Original application | Approved | None posted |
| Griseofulvin,Ultramicrosize125MG · tablet;oral | Griseofulvin, Ultramicrosize | Rx |
| Griseofulvin,Ultramicrosize250MG · tablet;oral | Griseofulvin, Ultramicrosize | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters